Frontiers in Bioengineering and Biotechnology (Jul 2023)
Repurposing the oncolytic virus VSV∆51M as a COVID-19 vaccine
- Almohanad A. Alkayyal,
- Almohanad A. Alkayyal,
- Manar Darwish,
- Reham Ajina,
- Reham Ajina,
- Saleh Y. Alabbas,
- Mohammed A. Alotaibi,
- Abeer Alsofyani,
- Abeer Alsofyani,
- Maha Bokhamseen,
- Maumonah Hakami,
- Omar A. Albaradie,
- Omar A. Albaradie,
- Abdulaziz M. Moglan,
- Abdulaziz M. Moglan,
- Sharif Hala,
- Sharif Hala,
- Abdullah Faisal Alsahafi,
- Abdullah Faisal Alsahafi,
- Samer Zakri,
- Samer Zakri,
- Adnan Almuzaini,
- Khamis Alsharari,
- Feras Kaboha,
- Mustafa Y. Taher,
- Haggag S. Zein,
- Haggag S. Zein,
- Fayhan Alroqi,
- Fayhan Alroqi,
- Fayhan Alroqi,
- Ahmad Bakur Mahmoud,
- Ahmad Bakur Mahmoud,
- Ahmad Bakur Mahmoud
Affiliations
- Almohanad A. Alkayyal
- Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia
- Almohanad A. Alkayyal
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Manar Darwish
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Reham Ajina
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Reham Ajina
- Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Saleh Y. Alabbas
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Mohammed A. Alotaibi
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Abeer Alsofyani
- Department of Cellular Therapy and Cancer Research, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia
- Abeer Alsofyani
- King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- Maha Bokhamseen
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Maumonah Hakami
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Omar A. Albaradie
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Omar A. Albaradie
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
- Abdulaziz M. Moglan
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Abdulaziz M. Moglan
- College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
- Sharif Hala
- King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- Sharif Hala
- Infectious Disease Research Department, King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- Abdullah Faisal Alsahafi
- King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- Abdullah Faisal Alsahafi
- Infectious Disease Research Department, King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- Samer Zakri
- King Saud Bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- Samer Zakri
- Infectious Disease Research Department, King Abdullah International Medical Research Centre, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia
- Adnan Almuzaini
- Experimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia
- Khamis Alsharari
- Experimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia
- Feras Kaboha
- Experimental Medicine Department, King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia
- Mustafa Y. Taher
- College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia
- Haggag S. Zein
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Haggag S. Zein
- 0Department of Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada
- Fayhan Alroqi
- Immunology Research Program, King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
- Fayhan Alroqi
- 1Department of Immunology, Ministry of the National Guard—Health Affairs, Riyadh, Saudi Arabia
- Fayhan Alroqi
- 2King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- Ahmad Bakur Mahmoud
- College of Applied Medical Sciences, Taibah University, Madinah, Saudi Arabia
- Ahmad Bakur Mahmoud
- 3Strategic Research and Innovation Laboratories, Taibah University, Madinah, Saudi Arabia
- Ahmad Bakur Mahmoud
- 4Immunology Research Program, King Abdullah International Medical Research Center, Jeddah, Saudi Arabia
- DOI
- https://doi.org/10.3389/fbioe.2023.1150892
- Journal volume & issue
-
Vol. 11
Abstract
The coronavirus disease 2019 (COVID-19) pandemic imposes an urgent and continued need for the development of safe and cost-effective vaccines to induce preventive responses for limiting major outbreaks around the world. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we repurposed the VSV∆51M oncolytic virus platform to express the spike receptor-binding domain (RBD) antigen. In this study, we report the development and characterization of the VSV∆51M-RBD vaccine. Our findings demonstrate successful expression of the RBD gene by the VSV∆51M-RBD virus, inducing anti-RBD responses without attenuating the virus. Moreover, the VSV∆51M-RBD vaccine exhibited safety, immunogenicity, and the potential to serve as a safe and effective alternative or complementary platform to current COVID-19 vaccines.
Keywords
